Loss of progesterone receptor through epigenetic regulation is associated with poor prognosis in solid tumors.

ABSTRACT:

Background

Hormonal therapy using progestins, acting through the progesterone receptor (PR), is a well-established method to treat uterine endometrial hyperplasia and carcinoma. Recent population studies indicate that progestin exposure significantly reduces the incidence of ovarian, pancreatic and lung cancers in addition to endometrial cancer in women. This unexpected differentiating function of progestin in organs outside of the reproductive system led us to hypothesize that progestins/PR are protective against cancer development and progression in many tumor types.

Methods

The Cancer Genome Atlas, Oncomine and Prognostic Databases were searched to determine the relative expression of PR in tumors from multiple sites, and clinical outcomes linked to PR expression were det

SUBMITTER: Li Y 

PROVIDER: S-EPMC7339273 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature